Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor Alpha

Drugs that kill tumors through multiple mechanisms have potential for broad clinical benefits, with a reduced propensity to resistance. We developed BipotentR, a computational approach to find cancer-cell-specific regulators that simultaneously modulate tumor immunity and another oncogenic pathway. Using tumor metabolism as proof-of-principle, BipotentR identified 38 candidate immune-metabolic regulators by combining epigenomes with bulk and single-cell tumor transcriptomes from patients. Inhibition of top candidate ESRRA (Estrogen Related Receptor Alpha) killed tumors by direct effects on energy metabolism and two immune mechanisms: (i) cytokine induction, causing proinflammatory macrophage polarization (ii) antigen-presentation stimulation, recruiting CD8+T cells into tumors. ESRRA is activated in immune-suppressive and immunotherapy-resistant tumors of many types, suggesting broad clinical relevance. We also applied BipotentR to angiogenesis and growth-suppressor pathways, demonstrating a widely applicable approach to identify drug targets that act simultaneously through multiple mechanisms. BipotentR is publicly available at http://bipotentr.dfci.harvard.edu/. One-Sentence Summary BipotentR identifies targets for bipotent anticancer drugs, as shown by the energy and immune effects of ESRRA inhibition.

[1]  Masafumi Nakamura,et al.  PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor , 2021, Translational oncology.

[2]  Clifford A. Meyer,et al.  Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. , 2021, Cancer discovery.

[3]  Liang He,et al.  NEBULA: a fast negative binomial mixed model for differential expression and co-expression analyses of large-scale multi-subject single-cell data , 2020, bioRxiv.

[4]  Fan Zhang,et al.  TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment , 2020, bioRxiv.

[5]  Clifford A. Meyer,et al.  Integrative analyses of single-cell transcriptome and regulome using MAESTRO , 2020, Genome Biology.

[6]  B. Haibe-Kains,et al.  Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer. , 2020, Cancer discovery.

[7]  L. Galluzzi,et al.  Immunomodulation by anticancer cell cycle inhibitors , 2020, Nature Reviews Immunology.

[8]  Chenwei Li,et al.  SciBet as a portable and fast single cell type identifier , 2020, Nature Communications.

[9]  Peng Jiang,et al.  Large-scale public data reuse to model immunotherapy response and resistance , 2020, Genome Medicine.

[10]  Clifford A. Meyer,et al.  Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data , 2020, Genome Biology.

[11]  Xiujie Chen,et al.  CHG: A Systematically Integrated Database of Cancer Hallmark Genes , 2020, Frontiers in Genetics.

[12]  N. Chandel,et al.  Mitochondrial TCA cycle metabolites control physiology and disease , 2020, Nature Communications.

[13]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[14]  Chunquan Li,et al.  KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors , 2019, Nucleic Acids Res..

[15]  Leonard J. Foster,et al.  Cell type prioritization in single-cell data , 2019, Nature Biotechnology.

[16]  T. Aittokallio,et al.  Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity. , 2019, Blood.

[17]  Yi Wei,et al.  Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy , 2019, Scientific Reports.

[18]  M. Verzi,et al.  HNF4 Regulates Fatty Acid Oxidation and is Required for Renewal of Intestinal Stem Cells in Mice. , 2019, Gastroenterology.

[19]  Clifford A. Meyer,et al.  Inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data , 2019, bioRxiv.

[20]  J. Powell,et al.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion , 2019, Science.

[21]  R. Tothill,et al.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer , 2019, Cancer cell.

[22]  R. Johnstone,et al.  Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. , 2019, Cell reports.

[23]  J. Settleman,et al.  Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance , 2019, bioRxiv.

[24]  R. Bernards,et al.  Inducing and exploiting vulnerabilities for the treatment of liver cancer , 2019, Nature.

[25]  Howard Y. Chang,et al.  Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.

[26]  Yonggong Zhai,et al.  PPARs as Nuclear Receptors for Nutrient and Energy Metabolism , 2019, Molecules.

[27]  T. Schumacher,et al.  Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold , 2019, Cell.

[28]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[29]  Virginia Savova,et al.  Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. , 2019, Immunity.

[30]  P. A. Futreal,et al.  Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. , 2019, Cancer discovery.

[31]  Wei Zhang,et al.  Dissecting intratumoral myeloid cell plasticity by single cell RNA‐seq , 2019, Cancer medicine.

[32]  N. Garg,et al.  Metabolic programming of macrophage functions and pathogens control , 2019, Redox Biology.

[33]  Howard Y. Chang,et al.  Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion , 2019, Nature Biotechnology.

[34]  V. Giguère,et al.  ERRα as a Bridge Between Transcription and Function: Role in Liver Metabolism and Disease , 2019, Front. Endocrinol..

[35]  G. Mills,et al.  Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy , 2019, Nature Metabolism.

[36]  Yaoqi Zhou,et al.  Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. , 2019, Cell metabolism.

[37]  M. Artyomov,et al.  Itaconate: the poster child of metabolic reprogramming in macrophage function , 2019, Nature Reviews Immunology.

[38]  Atul J. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[39]  T. Mogensen.  IRF and STAT Transcription Factors - From Basic Biology to Roles in Infection, Protective Immunity, and Primary Immunodeficiencies , 2019, Front. Immunol..

[40]  Xiaoyan Zhang,et al.  Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis , 2018, Nucleic Acids Res..

[41]  Christoph Hafemeister,et al.  Comprehensive integration of single cell data , 2018, bioRxiv.

[42]  Monika S. Kowalczyk,et al.  A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade , 2018, Cell.

[43]  Lei S. Qi,et al.  CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens , 2018, Genome Biology.

[44]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[45]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[46]  F. Sánchez‐Madrid,et al.  HDAC6 at Crossroads of Infection and Innate Immunity. , 2018, Trends in immunology.

[47]  P. Carmeliet,et al.  Phenotype molding of stromal cells in the lung tumor microenvironment , 2018, Nature Medicine.

[48]  S. Fakurazi,et al.  Targeting energy metabolism to eliminate cancer cells , 2018, Cancer management and research.

[49]  M. Wicha,et al.  Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. , 2018, Cell metabolism.

[50]  P. A. Futreal,et al.  Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer , 2018, Nature Medicine.

[51]  K. Brown,et al.  Tumor immune evasion arises through loss of TNF sensitivity , 2018, Science Immunology.

[52]  Z. Trajanoski,et al.  Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade , 2018, Nature Communications.

[53]  M. Shimojima,et al.  RIG-I-Like Receptor and Toll-Like Receptor Signaling Pathways Cause Aberrant Production of Inflammatory Cytokines/Chemokines in a Severe Fever with Thrombocytopenia Syndrome Virus Infection Mouse Model , 2018, Journal of Virology.

[54]  S. Feske,et al.  NFAT control of immune function: New Frontiers for an Abiding Trooper , 2018, F1000Research.

[55]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[56]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[57]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[58]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[59]  Clifford A. Meyer,et al.  Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer. , 2017, Cancer research.

[60]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[61]  Eyal Gottlieb,et al.  Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemic stem cells , 2017, Nature Medicine.

[62]  K. Swanson,et al.  Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma. , 2017, The Journal of investigative dermatology.

[63]  M. Carroll,et al.  Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.

[64]  G. Koehl,et al.  Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment , 2017, Front. Immunol..

[65]  N. Gray,et al.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors , 2017, Nature Communications.

[66]  A. Dejean,et al.  SUMO and the robustness of cancer , 2017, Nature Reviews Cancer.

[67]  T. Jiang,et al.  Inference of immune cell composition on the expression profiles of mouse tissue , 2017, Scientific Reports.

[68]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[69]  Tao Liu,et al.  Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse , 2016, Nucleic Acids Res..

[70]  Marc R. Birtwistle,et al.  Drug response consistency in CCLE and CGP , 2016, Nature.

[71]  A. D. de Vos,et al.  Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. , 2016, Cell reports.

[72]  Jeff S. Jasper,et al.  ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. , 2016, Cell reports.

[73]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[74]  K. Alfarouk.  Tumor metabolism, cancer cell transporters, and microenvironmental resistance , 2016, Journal of enzyme inhibition and medicinal chemistry.

[75]  K. Hoadley,et al.  Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting , 2016, Bladder cancer.

[76]  V. Boussiotis,et al.  The role of metabolic reprogramming in T cell fate and function. , 2016, Current trends in immunology.

[77]  J. Secombe,et al.  The Histone Demethylase KDM5 Activates Gene Expression by Recognizing Chromatin Context through Its PHD Reader Motif. , 2015, Cell reports.

[78]  K. Tam,et al.  Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? , 2015, International journal of biological sciences.

[79]  S. Biswas.  Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.

[80]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[81]  V. Giguère,et al.  Orphan Nuclear Receptor ERRα Controls Macrophage Metabolic Signaling and A20 Expression to Negatively Regulate TLR-Induced Inflammation. , 2015, Immunity.

[82]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[83]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[84]  Kai Li,et al.  Targeted exploration and analysis of large cross-platform human transcriptomic compendia , 2015, Nature Methods.

[85]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[86]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[87]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[88]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[89]  Hanfei Sun,et al.  Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.

[90]  Peng Tang,et al.  Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma. , 2013, World journal of gastroenterology.

[91]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[92]  Luke A. Gilbert,et al.  Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.

[93]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[94]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[95]  Gerhard Christofori,et al.  Transcription factor Dlx2 protects from TGFβ‐induced cell‐cycle arrest and apoptosis , 2011, The EMBO journal.

[96]  Michael J. Bevan,et al.  CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.

[97]  L. Nagy,et al.  PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation☆ , 2011, Biochimica et biophysica acta.

[98]  V. Giguère,et al.  Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease. , 2011, Biochimica et biophysica acta.

[99]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[100]  H. Askari,et al.  Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. , 2011, Journal of medicinal chemistry.

[101]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[102]  R. Zaru,et al.  TLR signalling regulated antigen presentation in dendritic cells. , 2010, Current opinion in immunology.

[103]  A. Fukamizu,et al.  A Combination of HNF-4 and Foxo1 Is Required for Reciprocal Transcriptional Regulation of Glucokinase and Glucose-6-phosphatase Genes in Response to Fasting and Feeding* , 2008, Journal of Biological Chemistry.

[104]  P. Calder.  The relationship between the fatty acid composition of immune cells and their function. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[105]  T. Taniguchi,et al.  The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.

[106]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.

[107]  D. Greaves,et al.  Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. , 2006, Cell metabolism.

[108]  G. Collins.  The next generation. , 2006, Scientific American.

[109]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[110]  X. Yang,et al.  Disruption of Smad5 gene induces mitochondria-dependent apoptosis in cardiomyocytes. , 2005, Experimental cell research.

[111]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[112]  P. Spellman,et al.  The SIN3 Deacetylase Complex Represses Genes Encoding Mitochondrial Proteins , 2003, Journal of Biological Chemistry.

[113]  A. Porgador,et al.  Immunization by gamma‐IFN‐treated B16‐F10.9 melanoma cells protects against metastatic spread of the parental tumor , 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[114]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.